Patients around the world are in urgent need of new therapies. Many have exhausted available treatment options and cannot wait for promising new medicines to be approved and commercialized. Combine this need with the increased transparency of drug development pipelines, more informed patients and delays in market availability, and you create plenty of demand for access to new innovative medicines that meet a high degree of unmet medical need. Fortunately, access programs (referred to by many terms including expanded access, named patient programs and compassionate use) can provide an ethical and regulatory-compliant solution. Unfortunately, there is a lack of awareness and understanding of how these programs work and the value offered to all stakeholders including patients, physicians and the sponsoring company.
As a result, these programs are not deployed enough in situations that can be of significant benefit to patients. Given the need and importance of these programs, it is essential that the pharmaceutical industry has an understanding of how they work and when best applied. On Tuesday, 14 October 2014, I will provide an overview of patient access programs and provide guidance on their development and implementation. Including regulatory guidelines and share insight into practical considerations that affect program execution, including patient eligibility, stakeholder involvement, timing and logistics. My talk will be based on a new ISPE white paper, Improving Access for Patients with Unmet Medical Needs – Overview and Best Practices for Success, which reflects a collaboration of an interdisciplinary team of industry experts. Join me and other speakers as we participate in Day 2 of the Investigational Products Track. For more details about the session check the educational listings here http://www.ispe.org/2014-annual-meeting/learn#education.
Since starting with ISPE, Edyna Miguez, has had the incredible opportunity to connect with women across the globe working within the pharmaceutical industry, as part of the ISPE Women in Pharma® program. The tenure of these rising female leaders varies, as do their cultural backgrounds. However, one fact remains consistent: they are looking to make the industry a more equitable and...
The ISPE GAMP® 5 Guide (Second Edition) was published on 29 July 2022. It was presented and discussed at the 2023 ISPE Europe Annual Conference, the 2023 ISPE Annual Meeting & Expo, and at several local...
The importance of the 2024 ISPE Europe Annual Conference is evident with the continuous challenges the pharmaceutical industry is facing in terms of drug shortages, regulatory requirements, digitalization, automation, and big data management.